Immunogenicity and tolerability of an AdVac-based tuberculosis vaccine in subjects previously vaccinated with BCG.

Trial Profile

Immunogenicity and tolerability of an AdVac-based tuberculosis vaccine in subjects previously vaccinated with BCG.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Feb 2010

At a glance

  • Drugs Tuberculosis vaccine (Primary)
  • Indications Tuberculosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Crucell
  • Most Recent Events

    • 18 Feb 2010 Results published in the American Journal of Respiratory and Critical Care Medicine.
    • 09 Apr 2008 Preliminary results reported in an Aeras/Crucell/SATVI media release.
    • 09 Apr 2008 Progress update and immunology data presented at the Tuberculosis Vaccines for the World conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top